Latest From NextCure Inc.
Emerging Company Profile: Based on discovery research at Yale, NextCure hopes S15 and other novel targets will provide new inroads in immuno-oncology, while much of the field remains focused on PD-1 inhibitors and combinations.
Scrip spoke with Managing Director Julie Sunderland about Biomatics' new $300m fund. Also, Silicon Valley Bank reveals its surprising Leerink buy, Perceptive Advisors raises $675m, Roivant brings in another $200m, and cell and gene therapy financings surge in the third quarter.
Through its Provention collaboration, Amgen partnered with the team that worked on AMG 714 at Celimmune, which the big biotech bought in 2017. Lilly will partner with NextCure to use the latter's FIND-IO platform for immuno-oncology drug discovery.
Series A venture capital and seed funding rounds for biopharma firms in 2016 kept pace with the level of investment seen in 2015, excluding one major deal in 2015, laying the foundation for optimism regarding early-stage financings in 2017 for particularly innovative companies.
- Large Molecule
- Therapeutic Areas
- North America
- Company Type
- Parent & Subsidiaries
- NextCure Inc.
- Senior Management
Michael Richman, Pres. & CEO
Steven P Cobourn, CFO
Solomon Langermann, PhD, SVP, Research
Kevin H Heller, MD, CMO
Timothy Mayer, PhD, VP, Bus. Dev.
- Contact Info
Phone: (240) 399-4900
9000 Virginia Manor Rd.
Beltsville, MD 20705
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.